Nordihydroguaiaretic Acid for Health & Longevity

Evidence Review created on 07/18/2026 using AI4L / Opus 4.8

Also known as: NDGA, Masoprocol, Larreastat, meso-Nordihydroguaiaretic Acid, Actinex

Motivation

Nordihydroguaiaretic acid (NDGA) is a plant compound found in the leaves of the creosote bush, a desert shrub also known as chaparral. It is a strong antioxidant, meaning it helps neutralize the reactive molecules that damage cells over time. Interest in it as a longevity compound grew after a rigorous animal-aging program found that it lengthened the lives of male laboratory mice, placing it in a small group of substances shown to slow some aspects of aging in mammals.

The plant has a long history in traditional medicine, and the compound was widely used as a food and fiber preservative in the 1950s before being pulled from food use after safety concerns. In the 1990s, teas and capsules made from the raw plant were linked to serious liver injury, which shaped much of the caution that surrounds it today. Against that backdrop, its unusually consistent effect on the lifespan of male mice stands out as a genuine scientific puzzle.

This review examines what is known about nordihydroguaiaretic acid: how it works in the body, the benefits and risks suggested by laboratory, animal, and limited human data, how it has been used, and where the most important open questions remain.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Masoprocol

Grokipedia files this compound under its International Nonproprietary Name, masoprocol, and the article covers the same molecule reviewed here — its origin in the creosote bush, its antioxidant and lipoxygenase-inhibiting activity, and its antineoplastic and anti-inflammatory properties.

Examine

No dedicated Examine.com article was found for nordihydroguaiaretic acid or chaparral. Examine focuses on widely marketed dietary supplements, and NDGA is a niche compound without an entry.

Not applicable — NDGA is not a prescription medication, so the prescription-drug exclusion note does not apply.

ConsumerLab

No dedicated ConsumerLab.com article was found for nordihydroguaiaretic acid. ConsumerLab tests and reviews commonly sold consumer supplement products, and NDGA is not among them.

Not applicable — NDGA is not a prescription medication, so the prescription-drug exclusion note does not apply.

Systematic Reviews

This section summarizes the systematic-review evidence that directly addresses nordihydroguaiaretic acid’s principal mechanism.

Targeting Mammalian 5-Lipoxygenase by Dietary Phenolics as an Anti-Inflammatory Mechanism: A Systematic Review - Giménez-Bastida et al., 2021

This systematic review evaluates how dietary phenolic compounds act on the 5-lipoxygenase (5-LOX) pathway, the enzyme system that generates inflammatory signaling molecules called leukotrienes. NDGA is identified as one of the phenolics that reduces the formation of these molecules in laboratory studies, but the authors conclude that human evidence for any of these compounds is sparse and inconclusive, underscoring how limited the clinical data on NDGA’s anti-inflammatory action remain.

Mechanism of Action

NDGA is a phenolic lignan — a two-ringed plant compound — carrying two catechol groups (paired hydroxyl groups on a ring) that give it its distinctive chemistry. Its actions are wide-ranging and not highly selective:

Antioxidant / free-radical scavenging: The two catechol rings donate electrons to neutralize reactive oxygen species (ROS, the unstable oxygen-containing molecules that damage cell components), which is thought to underlie much of its cell-protective effect.
Lipoxygenase inhibition: NDGA is a classic inhibitor of lipoxygenase enzymes, most notably 5-lipoxygenase (5-LOX) and also 12- and 15-lipoxygenase, blunting production of leukotrienes and related inflammatory lipids.
NRF2 activation: By mildly stressing cells, NDGA activates NRF2 (Nuclear factor erythroid 2–related factor 2, a master switch that turns on the cell’s own antioxidant and detoxification genes), boosting internal defenses rather than only scavenging directly.
Growth-signal and epigenetic effects: NDGA can inhibit the IGF-1 receptor (insulin-like growth factor 1 receptor, a growth-promoting receptor) and the HER2 receptor (another growth-promoting receptor), and it inhibits p300 (an enzyme that chemically tags proteins to switch genes on), an action linked to activation of autophagy (the cell’s internal recycling and clean-up process). Autophagy activation is a recurring theme among longevity interventions.
Metabolic effects: In animals, NDGA induces PPARα (a master regulator that switches on fat-burning genes), increasing the breakdown of fats in the liver.

The explanation of why NDGA extends lifespan remains genuinely contested. Competing accounts emphasize different mechanisms: one view holds that its antioxidant and lipoxygenase-blocking actions reduce chronic inflammation and oxidative damage; a competing view argues the lifespan effect is better explained by p300 inhibition and autophagy, or by NRF2-driven stress resistance, rather than by simple antioxidant activity. The strict male-only lifespan effect in mice is itself unexplained and is thought to relate to sex differences in how the compound is absorbed or broken down.

Key pharmacological properties, as a pharmacological compound: NDGA is poorly water-soluble and is rapidly metabolized, primarily by glucuronidation (attachment of a sugar group by UGT enzymes, which aids excretion) and by O-methylation via COMT (catechol-O-methyltransferase, the enzyme that inactivates catechol compounds); its catechols can also be oxidized to reactive quinones. Its plasma half-life is short (on the order of a few hours), it distributes widely across tissues, and it is not a selective single-target drug — a feature that complicates both its therapeutic use and its safety.

Historical Context & Evolution

Traditional origins: Creosote bush (chaparral) has been used for centuries in Native American and Mexican traditional medicine as a tea or poultice for complaints ranging from arthritis and infections to digestive problems, with NDGA as its principal active constituent.
Industrial antioxidant era: NDGA’s original modern use was industrial, not medical. Because it is a potent antioxidant, it was widely employed in the 1950s to prevent fats and oils from going rancid and to preserve natural fibers, and it was listed as a food additive.
Withdrawal from food use: In the 1960s, animal studies reported kidney damage — including cystic changes in the kidney and lymph nodes — with chronic NDGA feeding. On that basis it was removed from the United States list of substances “generally recognized as safe” for food use.
Reception versus findings: The historical safety signal was a real, reproducible finding of dose-related kidney lesions in rodents, not merely a regulatory judgment. Rather than being simply “banned,” NDGA was re-evaluated as evidence of chronic toxicity accumulated, and its food status changed accordingly; the underlying rodent data remain the basis for current caution.
Chaparral liver-injury reports: In the early 1990s, as chaparral was marketed as a herbal supplement, clusters of serious liver injury — including cases progressing to liver failure and transplantation — prompted health-authority warnings against oral chaparral products.
Pharmaceutical development: A topical form, masoprocol (Actinex), was approved in the United States in the early 1990s to treat sun-related skin lesions but was later withdrawn from the market, largely because of frequent skin-irritation and allergic reactions. Chemically modified derivatives such as terameprocol (tetra-O-methyl-NDGA) were subsequently developed to retain activity while reducing the reactive catechol chemistry.
Longevity turn: NDGA re-entered scientific attention in 2008 when the National Institute on Aging’s Interventions Testing Program reported that it extended the lifespan of male mice, reframing an old industrial antioxidant as a candidate aging intervention. Scientific opinion continues to evolve: the lifespan finding has been repeatedly reproduced, but the mechanism and the male-only limitation remain open, and no consensus has settled on whether the finding translates beyond rodents.

Expected Benefits

The evidence base is dominated by cell and animal studies. Benefit grades below reflect the strength of evidence for each effect and, critically, whether any human data exist. For this proactive, longevity-oriented audience, the central point is that NDGA’s most discussed benefit — lifespan extension — rests entirely on animal data and, so far, only in males.

High 🟩 🟩 🟩

The one benefit supported by human randomized controlled trial (RCT, a study that randomly assigns participants to treatment or a dummy comparator) evidence is dermatological. In a double-blind, vehicle-controlled trial, twice-daily topical masoprocol cream reduced the number of actinic keratoses (rough, sun-damaged skin patches that can precede skin cancer) far more than the inactive cream. This is a local, skin-surface effect and does not speak to any systemic or longevity benefit, but it is the highest-quality human efficacy signal the molecule has.

Magnitude: Median lesion reduction of about 71% with masoprocol versus roughly 4% with vehicle over 1 month (Olsen et al., 1991).

Medium 🟩 🟩

Lifespan Extension in Male Mammals

NDGA is one of a small number of compounds shown to extend median lifespan in genetically diverse mice, and this is the core of its longevity reputation. The National Institute on Aging Interventions Testing Program found the effect in males across three independent sites and later reproduced it at three different doses, a stringent standard rarely met by candidate longevity agents. The effect is strictly male-specific in mice, is not seen for maximal lifespan, and has never been tested for lifespan in humans; lifespan extension has also been reported in shorter-lived species such as fruit flies. The grade reflects reproducible controlled evidence in animals, not any human data.

Magnitude: Approximately 8–12% increase in median lifespan in male mice, with no significant effect on maximal lifespan and no benefit in females (Strong et al., 2008; Strong et al., 2016).

Low 🟩

Improvement of Blood Triglycerides and Fatty Liver

In several rodent models of diet-induced metabolic disease, NDGA lowered blood and liver triglycerides and reduced fat accumulation in the liver. In mice fed a fast-food-style diet, it normalized liver triglycerides and liver-injury enzymes and reduced body and fat-pad weight, effects tied to increased fat-burning through PPARα. These are consistent animal findings without human confirmation.

Magnitude: Normalization of elevated liver triglycerides and of the liver enzymes ALT and AST (measures of liver-cell injury) toward control levels in diet-challenged mice (Chan et al., 2018).

Improved Insulin Sensitivity

Related rodent work shows NDGA improves insulin sensitivity — how effectively the body responds to the blood-sugar hormone insulin — in obese and diet-challenged animals, though effects on overall glucose tolerance are inconsistent. The signal is mechanistically plausible and reproducible across models but, again, entirely preclinical.

Magnitude: Improved insulin sensitivity in diet-fed and genetically obese mice, without consistent improvement in glucose tolerance (Chan et al., 2018).

Anti-Inflammatory Activity

Through inhibition of 5-lipoxygenase, NDGA reduces the formation of leukotrienes, the inflammatory lipids that drive several inflammatory conditions. A systematic review of dietary phenolics confirms this action for NDGA in laboratory systems but finds human evidence lacking, so the real-world anti-inflammatory benefit in people is unestablished.

Magnitude: Not quantified in available studies.

Speculative 🟨

Neuroprotection

In animal models of neurodegenerative disease, NDGA has shown protective signals — extending survival in a mouse model of amyotrophic lateral sclerosis (a fatal motor-nerve disease), improving measures in Huntington’s disease models, and reducing amyloid deposits in Alzheimer’s models. These findings are early, model-dependent, and have not been tested in humans, so any neuroprotective benefit is mechanistic and speculative at present.

Anticancer Activity

NDGA and its derivatives inhibit tumor-cell growth in the laboratory through effects on growth-factor receptors, the arachidonic acid pathway, and gene-transcription machinery. Early-phase human trials of NDGA (in prostate cancer) and of the derivative terameprocol (in solid tumors, leukemia, and brain tumors) were conducted, but these were small and did not establish clinical efficacy, several closing early. Any anticancer benefit for this audience is speculative.

Antioxidant and Cardiovascular Effects

NDGA’s potent free-radical scavenging and its modulation of nitric-oxide signaling in blood-vessel cells suggest possible cardiovascular and general cell-protective benefits. These rest on laboratory and mechanistic data without controlled human outcomes, placing them firmly in the speculative category.

Benefit-Modifying Factors

Biological sex: The single most important modifier. In mice, the lifespan benefit occurs only in males, attributed to sex differences in how NDGA is absorbed or metabolized; whether metabolic and other benefits are similarly sex-limited is unknown but plausible.
Genetic polymorphisms: Variation in the genes for COMT (which inactivates catechol compounds) and UGT enzymes (which attach sugar groups to aid excretion) would be expected to alter NDGA blood levels and duration of action, potentially shifting both benefit and risk, though this has not been studied clinically.
Baseline metabolic status: The metabolic benefits in animals were seen against a backdrop of diet-induced disease (high triglycerides, fatty liver). Individuals with elevated triglycerides or fatty liver might, in principle, have more to gain than metabolically healthy individuals, in whom a floor effect would limit measurable benefit.
Baseline inflammatory and oxidative load: Because the compound acts on inflammation and oxidative stress, any benefit is likely larger where these are elevated at baseline and minimal where they are already low.
Pre-existing health conditions: Existing liver or kidney disease not only raises risk but may also blunt tolerability and thus limit any achievable benefit at usable doses.
Age: In aged mice, NDGA was associated with better physical-function measures; whether older humans within the target range would derive proportionally more or less benefit is untested.

Potential Risks & Side Effects

The safety profile is the defining concern with NDGA and, for a longevity audience, arguably outweighs the animal-only benefit signal. Unlike the benefits, several risks are documented in humans.

High 🟥 🟥 🟥

Hepatotoxicity (Liver Injury)

Oral chaparral and NDGA are established causes of liver injury in humans. Reported cases range from symptomless elevations in liver enzymes to acute hepatitis, and in a subset to acute liver failure requiring transplantation. The mechanism is thought to involve the oxidation of NDGA’s catechols to reactive quinones that damage liver proteins and DNA, an idiosyncratic injury that can appear weeks to months after starting use. This is the risk that most directly limits any longevity use of oral NDGA.

Magnitude: Dozens of published cases of clinically apparent liver injury linked to chaparral/NDGA, a minority progressing to liver failure or transplantation (NIH LiverTox).

Medium 🟥 🟥

Kidney Toxicity (Cystic Renal Disease)

Chronic NDGA exposure produced kidney damage in animals, including cystic changes in the kidney — the finding that originally removed it from food use — and human cases of kidney injury have been reported with chaparral. The risk appears tied to prolonged and higher-dose exposure rather than brief use.

Magnitude: Dose- and duration-related cystic kidney lesions in rodents; sporadic human renal-injury reports with chronic chaparral use (Arteaga et al., 2005).

Low 🟥

Skin Irritation and Contact Allergy (Topical)

The topical masoprocol form frequently caused local irritation — redness and flaking — and allergic contact dermatitis, which was a major reason the prescription cream was withdrawn from the market. This risk is specific to skin application rather than oral use.

Magnitude: Local irritation (erythema or flaking) in about 62% of masoprocol-treated patients versus 27% with vehicle (Olsen et al., 1991).

Gastrointestinal Upset

Oral chaparral has been associated with nausea, abdominal discomfort, and diarrhea, consistent with a plant extract taken by mouth. These effects are generally mild and reversible but are commonly reported.

Magnitude: Not quantified in available studies.

Speculative 🟨

Pro-Oxidant and Genotoxic Potential

Although NDGA is an antioxidant, its catechols can be oxidized to quinones that generate reactive oxygen species and form adducts with proteins and DNA. This “pro-oxidant paradox” raises a theoretical concern for cellular and genetic damage at higher exposures, but it is drawn from laboratory systems and its relevance to real-world human dosing is unproven.

Enzyme-Inhibition–Mediated Effects

NDGA can inhibit COMT and several drug-metabolizing enzymes in the laboratory. In principle this could disturb the handling of catechol neurotransmitters or of co-administered drugs, but the clinical significance in humans has not been established.

Risk-Modifying Factors

Genetic polymorphisms: Variants in COMT and UGT metabolizing enzymes could increase NDGA exposure and thereby the risk of liver and kidney toxicity; variants affecting liver antioxidant defenses (for example in the NRF2 pathway) might modify susceptibility to quinone-mediated injury.
Baseline liver and kidney biomarkers: Elevated baseline liver enzymes (ALT, AST) or reduced kidney filtration (eGFR, a calculated measure of kidney filtration rate) mark individuals in whom the organ-toxicity risks are amplified.
Biological sex: Because sex strongly influences NDGA metabolism in animals, sex may also influence toxicity thresholds, though human data are lacking.
Pre-existing health conditions: Existing liver disease (fatty liver, hepatitis, cirrhosis) or chronic kidney disease substantially raises the risk of serious harm; concurrent alcohol use or other liver stress compounds it.
Age: Older individuals more often have reduced organ reserve and take more medications, both of which raise the likelihood and consequences of liver or kidney injury.
Dose and duration: The most consistent modifier across species is cumulative exposure — higher doses and prolonged use drive the organ toxicities, whereas brief, low exposures are comparatively better tolerated.

Key Interactions & Contraindications

Hepatotoxic drugs (prescription): Combining NDGA with medications that can injure the liver — for example acetaminophen (paracetamol), methotrexate, amiodarone, isoniazid, or high-dose statins — poses an additive liver-injury risk. Severity: caution to avoid; consequence: potentiated liver damage.
Over-the-counter medications: NSAIDs (non-steroidal anti-inflammatory drugs such as ibuprofen, naproxen) add both kidney stress and, with acetaminophen, liver stress. Severity: caution; consequence: additive organ toxicity. NDGA’s effects on lipoxygenase and platelet lipids could also theoretically add to the effects of aspirin.
Anticoagulants and antiplatelet agents: Because NDGA affects lipoxygenase pathways involved in platelet function, combining it with blood thinners (warfarin, apixaban, clopidogrel) or aspirin carries a theoretical increased bleeding risk. Severity: caution; consequence: possible increased bleeding.
Drugs metabolized by, or competing with, catechol/liver enzymes: By inhibiting COMT, NDGA could raise levels of catechol drugs such as levodopa or methyldopa; by inhibiting drug-metabolizing enzymes it could raise levels of some co-administered drugs. Severity: caution; consequence: increased drug exposure and side effects.
Supplement interactions: Other potentially hepatotoxic botanicals — including green tea extract at high doses, kava, comfrey, and pennyroyal — should be regarded as additive liver risks with NDGA. Severity: caution to avoid; consequence: compounded liver injury.
Supplements with additive effects: Because NDGA lowers triglycerides and improves insulin sensitivity in animals, combining it with agents that do the same — omega-3 fatty acids (fish oil), berberine, or blood-sugar-lowering supplements — could be additive; and other antioxidant supplements (high-dose vitamin C or E) might blunt the mild oxidative-stress signaling through which NDGA activates cellular defenses.
Other interventions: Alcohol should be regarded as a significant additive hepatotoxic exposure.
Populations who should avoid it: Those with any liver disease (including fatty liver, hepatitis B/C, cirrhosis, or a history of drug-induced liver injury), those with chronic kidney disease (for example eGFR <60 mL/min/1.73 m²), pregnant or breastfeeding individuals, those already taking hepatotoxic medications, and anyone scheduled for surgery (bleeding and liver-stress concerns) should avoid oral NDGA. A mitigating action for the drug-interaction risks is to separate timing where feasible and to prioritize avoiding the combination rather than relying on monitoring alone.

Risk Mitigation Strategies

Baseline and follow-up liver testing: Before any use, establish baseline liver enzymes (ALT, AST, ALP (alkaline phosphatase), bilirubin); this mitigates the dominant hepatotoxicity risk by identifying pre-existing injury and enabling early detection of new injury. Repeat testing (for example at 4–6 weeks, then every 3 months) allows discontinuation before mild enzyme elevations progress to serious injury.
Baseline and periodic kidney testing: Check kidney filtration (eGFR) and creatinine at baseline and periodically (for example every 6–12 months) to guard against the cystic/renal toxicity documented with chronic exposure.
Avoid raw chaparral products: Because the human liver-failure cases are concentrated in crude chaparral tea and capsules of uncertain content, avoiding raw plant preparations directly reduces the highest-severity risk.
Limit dose and duration: Since organ toxicity is driven by cumulative exposure, keeping any use to low doses and short, defined periods rather than open-ended daily intake mitigates both liver and kidney risk.
Screen medications and supplements: Reviewing the full medication and supplement list for hepatotoxic, nephrotoxic, or bleeding-risk agents mitigates additive-toxicity and interaction risks; the mitigating action is to avoid the combination.
Stop at warning signs: Discontinuing immediately at symptoms of liver injury — unusual fatigue, nausea, right-upper-abdominal pain, dark urine, or yellowing of the skin or eyes — prevents progression of idiosyncratic hepatotoxicity to liver failure.

Therapeutic Protocol

There is no validated human protocol for using NDGA as a longevity or health-optimization intervention; what follows describes what has been used in research and the major open questions, not a recommended regimen.

No established longevity dose: No human study has tested oral NDGA for aging, healthspan, or metabolic outcomes, so no evidence-based dose, frequency, or duration exists for this purpose. The animal lifespan data used doses (expressed as parts per million in the diet) that do not translate straightforwardly to a human dose.
Doses used in research (context only): Early-phase oral NDGA cancer trials and the derivative terameprocol explored escalating doses under medical supervision with liver monitoring; these were experimental and are not a template for self-directed use. The topical masoprocol product was a 10% cream applied twice daily to the skin, an entirely different route from oral longevity use.
Competing approaches: Two distinct approaches appear in the literature without one being established as standard — using the parent compound NDGA (higher reactive-catechol chemistry, greater toxicity concern) versus using chemically modified derivatives such as terameprocol designed to reduce toxicity. Neither has been validated for longevity, and framing either as the default would overstate the evidence.
Best time of day: No timing has been established for any health outcome; the animal studies delivered NDGA continuously in food rather than as timed doses.
Half-life and dosing frequency: Given NDGA’s short plasma half-life (a few hours) and rapid metabolism, a single daily dose would be unlikely to sustain exposure, and continuous or divided dosing was used in animals — but no human dosing schedule is validated.
Single versus split doses: For the same pharmacokinetic reasons, divided dosing would be expected over a single daily dose if exposure were the goal, though this is inference, not established practice.
Genetic considerations: Individuals with COMT or UGT variants that slow catechol clearance could accumulate higher exposures; no pharmacogenetic dosing guidance exists.
Sex-based differences: The mouse lifespan benefit is male-only, raising the unresolved question of whether any protocol would even be expected to work in females; this alone argues against extrapolating a unisex regimen.
Age-related considerations: Older adults with reduced organ reserve and polypharmacy would face higher toxicity risk at any given dose, warranting greater caution rather than a defined adjusted dose.
Baseline biomarkers: Any use should be conditioned on normal baseline liver and kidney markers, as described in Monitoring.
Pre-existing conditions: Liver or kidney disease is a reason not to use the compound rather than a reason to adjust a protocol.

Discontinuation & Cycling

Lifelong versus short-term: There is no basis for lifelong human use; the documented organ toxicities are tied to chronic exposure, which argues against open-ended daily intake and in favor of short, monitored periods if used at all.
Withdrawal effects: No withdrawal syndrome has been described for NDGA; it is not known to cause physical dependence.
Tapering: Because there is no dependence or rebound described, no tapering protocol is established; the more relevant action is prompt discontinuation if liver or kidney markers worsen.
Cycling: No cycling schedule has been shown to maintain any benefit or reduce toxicity; cycling is sometimes proposed on general principles to limit cumulative exposure, but there is no evidence it preserves efficacy.

Sourcing and Quality

Regulatory and product landscape: NDGA is sold both as purified bulk powder and within chaparral (creosote bush) herbal products. Chaparral products have been the subject of health-authority warnings because of liver-injury cases, and there is no standardized, quality-assured consumer NDGA supplement category.
Purity and identity: Because crude chaparral preparations contain many constituents and variable NDGA content, purified NDGA of defined identity and assayed purity is preferable to raw plant material for reducing unpredictable exposure — though this does not make it safe.
Third-party testing: For any product used, independent third-party testing (for identity, assayed NDGA content, and contaminants such as heavy metals) is the relevant quality safeguard; the absence of an established testing framework for NDGA is itself a limitation buyers should weigh.
Reputable sources: There is no widely recognized reputable consumer brand or compounding standard specific to NDGA; research-grade material from established chemical suppliers is used in laboratories but is not intended for human consumption.

Practical Considerations

Time to effect: No human time-to-effect is established for any longevity or metabolic outcome. In animal metabolic studies, changes emerged over weeks of continuous dosing; the animal lifespan effect required lifelong exposure.
Common pitfalls: The most consequential pitfalls are using crude chaparral tea or capsules (the products linked to liver failure), assuming an “antioxidant” is inherently safe, extrapolating the male-mouse lifespan finding to humans of either sex, and using it without baseline and ongoing liver and kidney monitoring.
Regulatory status: NDGA is not an approved drug for any systemic indication; the former topical prescription product (masoprocol/Actinex) was withdrawn, and oral chaparral has drawn safety warnings. Any human use for longevity is off-label and unregulated.
Cost and accessibility: Purified NDGA and chaparral products are inexpensive and readily available online, which paradoxically lowers the barrier to a compound whose main documented human effect is organ toxicity.

Interaction with Foundational Habits

Sleep: The interaction is best characterized as none/indirect — there is no evidence that NDGA improves or disrupts sleep. No mechanism links it to the sleep–wake system, and no practical timing considerations apply.
Nutrition: The interaction is direct and potentiating in the metabolic context — in animals, NDGA’s benefits on triglycerides and liver fat were demonstrated specifically against high-fat, high-fructose “Western” diets, suggesting any benefit is entangled with diet quality. Practically, NDGA is not a substitute for reducing excess sugar and refined-fat intake, and its poor water solubility means absorption may vary with the fat content of a meal.
Exercise: The interaction is indirect and potentially blunting — as an antioxidant, high-dose NDGA could in theory dampen the beneficial oxidative-stress signaling that drives some exercise adaptations, a concern shared by other strong antioxidants; there is no NDGA-specific human data, but timing high-dose antioxidants away from key training sessions is a commonly discussed precaution.
Stress management: The interaction is indirect — by activating the NRF2 cellular-defense pathway, NDGA acts on the same stress-resistance machinery engaged by other mild-stress (“hormetic”) interventions, but there is no evidence it affects the cortisol or psychological stress response, and no practical steps are established.

Monitoring Protocol & Defining Success

Given that NDGA’s principal documented human effects are on the liver and kidney, monitoring centers on protecting those organs and, secondarily, on tracking any metabolic response.

Baseline testing (before starting) should establish liver and kidney status and metabolic markers so that any change can be detected early; testing should not be inferred only from the table below but performed deliberately as a precondition of use.

Ongoing monitoring should follow a defined cadence: liver enzymes at roughly 4–6 weeks after starting, then every 3 months; kidney function every 6–12 months; and metabolic markers at baseline and every 3–6 months if metabolic change is the goal.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
ALT (alanine aminotransferase)	<25 U/L (men), <20 U/L (women)	Detects liver-cell injury, the main NDGA hazard	Conventional labs flag only >40–55 U/L; the tighter functional range catches earlier injury. Fasting not required
AST (aspartate aminotransferase)	<25 U/L	Complements ALT for liver injury	Best interpreted paired with ALT; can also rise with muscle activity
ALP (alkaline phosphatase)	40–100 U/L	Flags bile-flow/liver involvement	Helps distinguish the pattern of any liver injury
Total bilirubin	<1.0 mg/dL	Marker of overall liver function	A rise alongside enzyme elevation signals more serious injury
GGT (gamma-glutamyl transferase)	<25 U/L	Sensitive marker of liver and oxidative stress	Elevated by alcohol; useful to track exposure burden
Creatinine / eGFR	eGFR >90 mL/min/1.73 m²	Detects the kidney toxicity seen with chronic use	Conventional threshold for concern is eGFR <60; hydration and muscle mass affect creatinine
Fasting triglycerides	<80 mg/dL	Tracks the main metabolic benefit target	Requires a 12-hour fast; conventional “normal” is <150 mg/dL
Fasting insulin	<6 µIU/mL	Tracks insulin sensitivity	Pair with fasting glucose; draw fasting, ideally morning

Qualitative markers to track alongside labs:

Energy levels and unusual fatigue (fatigue can be an early sign of liver injury)
Appetite, nausea, or right-upper-abdominal discomfort
Any yellowing of skin or eyes or darkening of urine (stop immediately and seek care)
General well-being and, where metabolic change is the aim, waist circumference and body weight

Emerging Research

The human research pipeline for NDGA itself is thin and has largely stalled; most recent clinical activity involves the safer derivative terameprocol rather than the parent compound.

Derivative in brain-tumor trials: Terameprocol in Treating Patients With Recurrent High Grade Glioma (NCT02575794) — a Phase 1 trial of the tetra-O-methyl NDGA derivative in aggressive brain tumors, enrolling about 20 participants, completed in 2023. It reflects the shift away from the toxic parent compound toward engineered analogs.
Parent-compound cancer trials (now closed): Pharmacokinetic and Efficacy Study of Nordihydroguaiaretic Acid (NDGA) in Non Metastatic Recurrent Prostate Cancer (NCT00678015) — a small Phase 2 study of oral NDGA that was terminated, illustrating the practical difficulties (including tolerability) of developing oral NDGA and part of why no active longevity trials exist.
No active longevity trials: As of the knowledge cutoff, there are no recruiting human trials of NDGA for aging, healthspan, or metabolic longevity endpoints; the longevity case rests on animal work from the Interventions Testing Program.
Mechanism of lifespan extension (could strengthen): Work identifying p300 inhibition and autophagy activation (Tezil et al., 2019) as a lifespan-relevant mechanism could strengthen the rationale if a safer way to engage the same pathway is found, and could explain the effect across species.
Metabolic and fatty-liver applications (could strengthen): Rodent evidence that NDGA improves diet-induced metabolic dysfunction (Chan et al., 2018) motivates possible human study in fatty liver and metabolic disease — an area where a favorable benefit-risk balance would need to be demonstrated.
Sex-difference and translation questions (could weaken): The unexplained male-only lifespan effect and the absence of any human longevity data are the areas most likely to weaken the case; if the effect proves specific to rodent male physiology or fails to separate from toxicity in humans, the longevity rationale would not hold.
Safer analog development (could strengthen or weaken): Continued development of derivatives that keep activity while shedding the reactive catechol chemistry could either rescue the therapeutic idea or, if the reactive chemistry proves essential to the benefit, confirm that the parent compound’s risk cannot be engineered away.

Conclusion

Nordihydroguaiaretic acid is a strong plant antioxidant from the creosote bush with an unusual profile: a genuinely reproducible signal of longer life in male mice sits alongside a well-documented history of serious liver injury in people. Its most discussed benefit — a longer lifespan — comes entirely from animals, appears only in males, and has never been tested in humans. Other benefits, such as lower blood fats, a less fatty liver, better response to the blood-sugar hormone, and reduced inflammation, are supported only by laboratory and animal studies. The one benefit shown in people is a skin-surface effect from a cream, not a whole-body or longevity effect.

On the other side of the ledger, oral use of the raw plant and of the compound has caused liver injury severe enough, in some cases, to require a transplant, and long-term use has damaged the kidneys in animals. The evidence base is uneven: strong and repeated in mice, thin and mostly negative or absent in humans, with no human longevity data at all. Taken together, the compound illustrates how a striking animal finding can coexist with real human hazard, and how much remains unknown about whether any of its promise carries over to people.

Top - Benefits - Risks - Protocol

Nordihydroguaiaretic Acid for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Reduction of Sun-Related Skin Lesions (Topical Masoprocol)

Medium 🟩 🟩

Lifespan Extension in Male Mammals

Low 🟩

Improvement of Blood Triglycerides and Fatty Liver

Improved Insulin Sensitivity

Anti-Inflammatory Activity

Speculative 🟨

Neuroprotection

Anticancer Activity

Antioxidant and Cardiovascular Effects

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Hepatotoxicity (Liver Injury)

Medium 🟥 🟥

Kidney Toxicity (Cystic Renal Disease)

Low 🟥

Skin Irritation and Contact Allergy (Topical)

Gastrointestinal Upset

Speculative 🟨

Pro-Oxidant and Genotoxic Potential

Enzyme-Inhibition–Mediated Effects

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion